Xpert MTB/RIF Ultra for Tuberculosis Testing in Children: A Mini-Review and Commentary

Rachel R Atherton, Fiona V Cresswell, Jayne Ellis, Sabrina B Kitaka, David R Boulware, Rachel R Atherton, Fiona V Cresswell, Jayne Ellis, Sabrina B Kitaka, David R Boulware

Abstract

Tuberculosis (TB) remains a significant, yet under-recognized cause of death in the pediatric population, with a WHO estimate of 1 million new cases of childhood TB in 2016 resulting in 250,000 deaths. Diagnosis is notoriously difficult; manifestations are protean due to the high proportion of cases of extra-pulmonary TB in children, and logistical problems exist in obtaining suitable specimens. These issues are compounded by the paucibacillary nature of disease with the result that an estimated 96% of pediatric TB-associated mortality occurs prior to commencing anti-tuberculous treatment. Further development of sensitive, rapid diagnostic tests and their incorporation into diagnostic algorithms is vital in this population, and central to the WHO End-TB strategy. Initial gains were made with the expansion of nucleic acid amplification technology, particularly the introduction of the GeneXpert fully-automated PCR Xpert MTB/Rif assay in 2010, and more recently, the Xpert MTB/Rif Ultra (Ultra) assay in 2017. Ultra provides increased analytical sensitivity when compared with the initial Xpert assay in vitro; a finding now also supported by six clinical studies to date, two of which included pediatric samples. Here, we review the published evidence for the performance of Ultra in TB diagnosis in children, as well as studies in adults with paucibacillary disease providing results relevant to the pediatric population. Following on from this, we speculate upon future directions for Ultra, with focus on its potential use with alternative diagnostic specimens, which may be of particular utility in children.

Keywords: TB; Ultra; Xpert; accuracy; children; pediatric; sensitivity; tuberculosis.

References

    1. WHO Global Tuberculosis Report 2017. (2017).
    1. Hesseling AC, Schaaf HS, Gie RP, Starke JR, Beyers N. A critical review of diagnostic approaches used in the diagnosis of childhood tuberculosis. Int J Tuberc Lung Dis. (2002) 6:1038–45.
    1. Kim WS, Choi JI, Cheon JE, Kim IO, Yeon KM, Lee HJ. Pulmonary tuberculosis in infants: radiographic and CT findings. AJR Am J Roentgenol. (2006) 187:1024–33. 10.2214/AJR.04.0751
    1. Schumacher SG, van Smeden M, Dendukuri N, Joseph L, Nicol MP, Pai M, et al. . Diagnostic test accuracy in childhood pulmonary tuberculosis: a Bayesian latent class analysis. Am J Epidemiol. (2016) 184:690–700. 10.1093/aje/kww094
    1. Kunkel A, Abel Zur Wiesch P, Nathavitharana RR, Marx FM, Jenkins HE, Cohen T. Smear positivity in paediatric and adult tuberculosis: systematic review and meta-analysis. BMC Infect Dis. (2016) 16:282. 10.1186/s12879-016-1617-9
    1. Marais BJ, Graham SM. Childhood tuberculosis: a roadmap towards zero deaths. J Paediatr Child Health. (2016) 52:258–61. 10.1111/jpc.12647
    1. WHO The End TB Strategy. WHO (2015).
    1. WHO Automated Real-time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System: Policy Statement. Geneva: World Health Organization; (2011).
    1. WHO Policy Update: Xpert MTB/RIF Assay for the Diagnosis of Pulmonary and Extrapulmonary TB in Adults and Children (2014). Geneva.
    1. Detjen AK, DiNardo AR, Leyden J, Steingart KR, Menzies D, Schiller I, et al. . Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children: a systematic review and meta-analysis. Lancet Respir Med. (2015) 3:451–61. 10.1016/S2213-2600(15)00095-8
    1. Kaur R, Kachroo K, Sharma JK, Vatturi SM, Dang A. Diagnostic accuracy of Xpert test in tuberculosis detection: a systematic review and meta-analysis. J Global Infect Dis. (2016) 8:32–40. 10.4103/0974-777X.176143
    1. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. (2014) Cd009593. 10.1002/14651858.CD009593
    1. Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B, et al. . Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. (2018) 18:76–84. 10.1016/S1473-3099(17)30691-6
    1. Cepheid 2017 launch of new TB test Ultra backed by WHO recommendation. (2017).
    1. Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, et al. . The new xpert MTB/RIF ultra: improving detection of mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. mBio (2017) 8:e00812–17. 10.1128/mBio.00812-17
    1. Nicol MP, Workman L, Prins M, Bateman L, Ghebrekristos Y, Mbhele S, et al. . Accuracy of xpert MTB/RIF ultra for the diagnosis of pulmonary tuberculosis in children. Pediatr Infect Dis J. (2018) 37:e261–3. 10.1097/INF.0000000000001960
    1. Sabi I, Rachow A, Mapamba D, Clowes P, Ntinginya NE, Sasamalo M, et al. . Xpert MTB/RIF Ultra assay for the diagnosis of pulmonary tuberculosis in children: a multicentre comparative accuracy study. J Infect. (2018) 77:321–7. 10.1016/j.jinf.2018.07.002
    1. Bahr NC, Nuwagira E, Evans EE, Cresswell FV, Bystrom PV, Byamukama A, et al. . Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study. Lancet Infect Dis. (2018) 18:68–75. 10.1016/S1473-3099(17)30474-7
    1. Perez-Risco D, Rodriguez-Temporal D, Valledor-Sanchez I, Alcaide F. Evaluation of the Xpert MTB/RIF ultra assay for direct detection of Mycobacterium tuberculosis complex in smear-negative extrapulmonary samples. J Clin Microbiol. (2018) 56:e00659–18. 10.1128/JCM.00659-18
    1. Bahr NC, Tugume L, Rajasingham R, Kiggundu R, Williams DA, Morawski B, et al. . Improved diagnostic sensitivity for tuberculous meningitis with Xpert® MTB/RIF of centrifuged CSF. Int J Tuberc Lung Dis. (2015) 19:1209–15. 10.5588/ijtld.15.0253
    1. Kyu HH, Maddison E, Henry N, Mumford JE, Barber RM, Shields C, et al. The global burden of tuberculosis: results from the Global Burden of disease study 2015. Lancet Infect Dis. (2018) 18:261–84. 10.1016/S1473-3099(17)30703-X
    1. Villanueva P, Neth O, Ritz N, Tebruegge M. Use of Xpert MTB/RIF Ultra assays among paediatric tuberculosis experts in Europe. Eur Respir J. (2018) 51:1800346. 10.1183/13993003.00346-2018
    1. Penz E, Boffa J, Roberts DJ, Fisher D, Cooper R, Ronksley PE, et al. . Diagnostic accuracy of the Xpert(R) MTB/RIF assay for extra-pulmonary tuberculosis: a meta-analysis. Int J Tuberc Lung Dis. (2015) 19:278–84, i–iii. 10.5588/ijtld.14.0262
    1. Lawn SD, Gupta-Wright A. Detection of lipoarabinomannan (LAM) in urine is indicative of disseminated TB with renal involvement in patients living with HIV and advanced immunodeficiency: evidence and implications. Trans R Soc Trop Med Hyg. (2016) 110:180–5. 10.1093/trstmh/trw008
    1. Feasey NA, Banada PP, Howson W, Sloan DJ, Mdolo A, Boehme C, et al. . Evaluation of Xpert MTB/RIF for detection of tuberculosis from blood samples of HIV-infected adults confirms Mycobacterium tuberculosis bacteremia as an indicator of poor prognosis. J Clin Microbiol. (2013) 51:2311–6. 10.1128/JCM.00330-13
    1. Walters E, Demers AM, van der Zalm MM, Whitelaw A, Palmer M, Bosch C, et al. . Stool culture for diagnosis of pulmonary tuberculosis in children. J Clin Microbiol. (2017) 55:3355–65. 10.1128/JCM.00801-17
    1. Auld AF, Fielding KL, Gupta-Wright A, Lawn SD. Xpert MTB/RIF — why the lack of morbidity and mortality impact in intervention trials? Trans R Soc Trop Med Hyg. (2016) 110:432–44. 10.1093/trstmh/trw056
    1. Pantoja A, Fitzpatrick C, Vassall A, Weyer K, Floyd K. Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis. Eur Respir J. (2013) 42:708–20. 10.1183/09031936.00147912
    1. Langley I, Lin HH, Egwaga S, Doulla B, Ku CC, Murray M, et al. . Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach. Lancet Global Health (2014) 2:e581–91. 10.1016/S2214-109X(14)70291-8
    1. Pinto M, Steffen RE, Cobelens F, van den Hof S, Entringer A, Trajman A. Cost-effectiveness of the Xpert(R) MTB/RIF assay for tuberculosis diagnosis in Brazil. Int J Tuberc Lung Dis. (2016) 20:611–8. 10.5588/ijtld.15.0455
    1. Vassall A, Siapka M, Foster N, Cunnama L, Ramma L, Fielding K, et al. . Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation. Lancet Global Health (2017) 5:e710–e9. 10.1016/S2214-109X(17)30205-X
    1. Vassall A, van Kampen S, Sohn H, Michael JS, John KR, den Boon S, et al. . Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med. (2011) 8:e1001120. 10.1371/journal.pmed.1001120

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren